Summary & Overview
CPT 81426: Whole Genome Reference Sequencing for Unexplained Disorders
CPT code 81426 is a specialized genetic testing procedure involving whole genome sequencing of a patient's relative to establish a reference genome for comparison. This approach is crucial in evaluating unexplained disorders or syndromes, offering clinicians a powerful tool for identifying genetic causes when conventional diagnostics fall short. The code is recognized by major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, reflecting its clinical importance and broad coverage.
This publication provides an in-depth overview of 81426, including payer coverage, clinical context, and relevant benchmarks. Readers will gain insight into the procedure's role in medical genetics, typical sites of service, and its relationship to other genetic testing codes. Policy updates and billing considerations are also discussed, helping stakeholders understand the evolving landscape of genetic testing reimbursement. The analysis highlights the significance of whole genome reference sequencing in advancing personalized medicine and improving diagnostic accuracy for complex cases.
CPT Code Overview
CPT code 81426 represents a comprehensive gene sequence analysis of the entire genome in a relative of the patient. This procedure is performed to create a reference genome gene sequence, which is then compared to the patient's genome to evaluate unexplained disorders or syndromes. The service type is genetic testing, and it is typically conducted in an office setting (Place of Service 11). This advanced analysis supports clinical decision-making in cases where a patient's condition cannot be explained by standard diagnostic methods.
Clinical & Coding Specifications
Clinical Context
A patient presents with an unexplained disorder or syndrome that has not been diagnosed through standard clinical evaluation. The clinician suspects a genetic etiology and orders a comprehensive genome sequencing analysis. To aid in interpretation, a relative of the patient (such as a parent or sibling) undergoes whole genome sequencing to create a reference genome. The laboratory compares the patient's genome to the relative's reference genome to identify potential pathogenic variants. This workflow is typically performed in an office setting (Place of Service 11) and is managed by specialists in medical genetics.
Coding Specifications
-
Modifiers:
- Modifier
26: Used to indicate the professional component of the service, such as interpretation and reporting by the physician or geneticist. - Modifier
59: Used to denote a distinct procedural service, indicating that the procedure is separate from other services performed on the same day.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207SG0201X | Medical Genetics, Ph.D. Medical Genetics |
207SC0300X | Medical Genetics, Clinical Genetics (M.D.) |
207SG0202X | Medical Genetics, Clinical Biochemical Genetics |
207SG0203X | Medical Genetics, Clinical Molecular Genetics |
207SG0205X | Medical Genetics, Clinical Cytogenetics |
These taxonomies represent providers specializing in various aspects of medical genetics, including clinical, biochemical, molecular, and cytogenetic genetics.
Related Diagnoses
Z80.3: Family history of malignant neoplasm of breast- Indicates a family history of breast cancer, supporting the need for genetic evaluation.
C50.919: Malignant neoplasm of unspecified site of unspecified female breast- Represents a diagnosis of breast cancer, which may prompt genetic testing for hereditary syndromes.
D48.60: Neoplasm of uncertain behavior of breast- Used when a breast neoplasm's behavior is unclear, warranting further genetic investigation.
Z15.01: Genetic susceptibility to malignant neoplasm of breast- Indicates a known genetic risk for breast cancer, justifying comprehensive genetic analysis.
Z84.81: Family history of carrier of genetic disease- Supports genetic testing based on family history of genetic disease carriers.
Each diagnosis code is clinically relevant to 81426 as they provide justification for genetic testing to evaluate unexplained disorders or hereditary cancer risk.
Related CPT Codes
81211: BRCA1, BRCA2 gene analysis, full sequence analysis- Used for targeted sequencing of BRCA1 and BRCA2 genes, often in cases of suspected hereditary breast cancer.
81212: BRCA1, BRCA2 gene analysis, known familial variants- Used when a specific familial variant is already identified and testing is performed for that variant.
81213: BRCA1, BRCA2 gene analysis, duplication/deletion variants- Used to detect large rearrangements in BRCA1 and BRCA2 genes.
81432: Hereditary breast cancer-related disorders, 5-50 genes- Used for panel testing of multiple genes associated with hereditary breast cancer.
81433: Hereditary breast cancer-related disorders, 51 or more genes- Used for expanded panel testing covering a broader range of genes.
These codes are related to 81426 as they represent genetic testing for hereditary cancer syndromes. 81426 is used for whole genome sequencing in a relative to create a reference for comparison, while the related codes focus on targeted or panel testing. Some codes may be used together in complex cases, while others serve as alternatives depending on clinical indications.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 81426 among commercial payers (BUCA average) is $1,907.71, which is substantially higher than the Aetna mean rate of $586.71. Blue Cross Blue Shield, Cigna, and UnitedHealth Group all report mean rates above $2,000, with UnitedHealth Group at $2,145.23, the highest among the listed payers.
Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $2,344.50 between its 75th and 25th percentiles, indicating substantial variability in reimbursement. In contrast, Blue Cross Blue Shield shows a tighter range of $1,221.50, and UnitedHealth Group's range is $1,328.00. Aetna's percentiles are all zero, suggesting limited or no payment for most providers.
The table and chart below present the full breakdown of national mean rates and percentile distributions for each payer.
State Benchmarks
State: AK1 / 50
Alaska Benchmarks
Alaska exhibits a wide rate spread for CPT code 81426 across commercial payers. The largest spread is seen with UnitedHealth Group, where the 25th percentile ($5,019.00) and 75th percentile ($5,420.00) are both substantially higher than other payers, indicating a consistently high reimbursement. Blue Cross Blue Shield and BUCA also show notable spreads, with BUCA's 75th percentile ($4,559.10) nearly $1,600 above its 25th percentile ($2,957.60). Aetna's rates are lower overall, with both the 25th and 50th percentiles at $0.00, suggesting limited reimbursement at those levels.
Compared to national averages, Alaska's mean rates for all payers are markedly higher. For example, UnitedHealth Group's mean rate in Alaska is more than double its national mean, and Blue Cross Blue Shield's mean rate is nearly $1,600 above the national average. The table and chart below present the full breakdown of payer-specific rates in Alaska for CPT code 81426.
Key Insights for Alaska
- UnitedHealth Group is the highest paying payer for CPT 81426 in Alaska, with a mean rate of $4,898.31.
- Aetna is the lowest paying payer, with a mean rate of $1,996.42.
- All Alaska payer mean rates are significantly higher than their respective national averages, with UnitedHealth Group and Blue Cross Blue Shield showing the largest deviations.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.